Peptide Therapy Protocols: A Functional Medicine Practitioner's Guide

Peptide therapy is exploding in FM and integrative medicine. BPC 157 alone is searched over 300,000 times a month. Your patients are already asking — they've seen the YouTube videos, read the forums, and some have already self-sourced before you've heard the word.

This guide gives you the FM practitioner's practical framework — from mechanisms to protocols to documentation. It's the pillar article for the peptide therapy silo; the support articles go deeper on specific applications.

What Are Peptides?

Peptides are short chains of amino acids (typically 2–50 amino acids) that function as biological signaling molecules. They are not hormones (larger proteins), and they are not small-molecule drugs (synthetic compounds). They sit in a unique space — signaling molecules that modulate endogenous processes.

The key concept: peptides work by upregulating or modulating endogenous processes — they don't override physiology, they signal it. They tell the body to heal itself more aggressively, to repair tissue more efficiently, to reduce inflammation more effectively. This is fundamentally different from taking a drug that blocks or replaces a function.

Why the FM model is well-suited to peptide therapy:

• Root-cause framework — peptides address mechanisms, not symptoms
• Complex, multi-intervention protocols — FM practitioners are already comfortable with stacking
• Monitoring culture — FM practitioners already track labs and outcomes over time
• Patient population — FM patients are often those who've exhausted conventional options and are motivated to try advanced interventions

Peptides have been in research for decades, used in elite sports medicine, and are now migrating into FM practice. The evidence base is mostly animal data with some emerging human data — not different from many FM interventions we use daily.

The FM Peptide Toolkit

BPC 157

• Origin: Gastric pentadecapeptide fragment — found naturally in human gastric juice
• Primary uses: Gut healing, tendon/ligament repair, post-surgical recovery, systemic anti-inflammatory
• Key mechanism: Angiogenesis upregulation via VEGF, growth hormone receptor sensitization, fibroblast activation, tight junction repair
• FDA status: Not approved; placed on FDA "difficult to compound" list in 2023

Thymosin Beta-4 (TB-500/TB4)

• Origin: Thymic peptide, naturally occurring in humans
• Primary uses: Tissue repair, anti-inflammatory, neurological recovery, wound healing
• Key mechanism: Actin sequestration (reduces oxidative stress), NF-κB inhibition, M2 macrophage polarization
• FDA status: Not approved for human use

CJC-1295 / Ipamorelin (GH Secretagogue Stack)

• CJC-1295: GHRH analog — stimulates pituitary GH release
• Ipamorelin: Ghrelin mimetic — selective GH secretagogue
• Used together for pulsatile GH release without the cortisol/prolactin spike seen with less selective secretagogues
• Primary uses: Body composition, recovery, sleep quality, anti-aging, IGF-1 optimization
• FDA status: Not approved for human use

GHK-Cu (Copper Peptide)

• Origin: Endogenous peptide; serum levels decline with age (~200 ng/mL at age 20, ~80 ng/mL at age 60)
• Primary uses: Wound healing, anti-inflammatory, collagen synthesis, cognitive support, tissue remodeling
• Key mechanism: Gene regulation (>4,000 genes modulated), TNF-α/IL-6 downregulation, IL-10/TGF-β upregulation
• FDA status: Not approved; used in research and compounded formulations

GLP-1 Agonists (Semaglutide / Tirzepatide)

• Status: FDA-approved for weight loss and type 2 diabetes (Ozempic, Wegovy, Mounjaro)
• FM angle: Beyond weight loss — metabolic inflammation, insulin sensitivity, gut motility, satiety signaling
• Different legal landscape — this is the only major peptide category with FDA-approved clinical use
• Compounding: Available through 503A/503B pharmacies during shortage exceptions

Brief Mentions

• KPV: Gut-specific anti-inflammatory (melanocortin receptor agonism); excellent for IBD
• Semax/Selank: Cognitive peptides; nasal delivery; emerging use in FM
• PT-141: Sexual function (melanocortin analog); niche use
• Epithalon: Telomere length; longevity research; limited FM use

Dosing Principles

General principles across all peptides:

Start low, titrate slowly. Most protocols begin at the lower end of the dosing range and titrate based on response.

Cycle protocols. Don't run indefinitely. Most peptide protocols are 12–16 weeks, followed by a break. This is precautionary — no receptor downregulation has been observed, but cycling is the clinical standard.

Route of administration matters:

• SubQ injection: most bioavailable for systemic effects
• Oral/sublingual: for gut-specific peptides (BPC 157, KPV) where local action is desired
• Intranasal: for cognitive peptides (Semax, Selank)
• Topical: for GHK-Cu skin/wound applications

Typical Dosing Windows

Peptide	Typical Dose	Route	Cycle Length
BPC 157	250–500 mcg/day	SubQ or oral	4–12 weeks
TB4 (TB-500)	2–5 mg 2x/week	SubQ	4–6 weeks loading, then monthly
CJC-1295	100–300 mcg	SubQ	8–12 weeks
Ipamorelin	100–300 mcg	SubQ	8–12 weeks
GHK-Cu	1–2 mg/day	SubQ	8–12 weeks

These are clinically observed ranges from compounding pharmacy guidelines and practitioner forums. Individualize based on patient factors and confirm against current compounding standards.

Ordering and Sourcing

GLP-1 (Semaglutide, Tirzepatide)

• FDA-approved — prescribe via normal channels
• Compounding available through 503A/503B pharmacies during shortage exceptions
• Different regulatory pathway than other peptides

Compounded Peptides (503A/503B Pharmacies)

• Highest quality standard for non-FDA-approved peptides
• Physician supervision required
• Requires prescription
• Quality verification: COAs (certificates of analysis), sterility testing, peptide purity ≥99%, endotoxin testing
• Trusted compounding partners: Tailor Made Health, Empower Pharmacy, Olympia Pharmacy, Wells Pharmacy — verify current status as FDA landscape shifts

Research Chemical Suppliers

• Not FDA-regulated
• Not for clinical use
• Acknowledge this landscape exists — patients may self-source
• If patient self-sources: document that you reviewed their protocol and are monitoring for safety; do NOT prescribe research chemicals

What to Look For in Compounding Partners

• Certificate of Analysis (COA) for every batch
• Sterility testing documentation
• Peptide purity ≥99%
• Endotoxin testing
• Third-party lab verification
• Clear communication about FDA regulatory changes

Patient Selection

BPC 157 Candidates

• Gut permeability, IBD, tendinopathies, post-surgical healing, NSAID damage
• Best when there's a specific healing deficit to address
• Not indicated for general wellness

TB4 Candidates

• Post-injury, fibromyalgia, neuroinflammation, chronic Lyme, post-COVID
• Systemic anti-inflammatory needs without primary gut involvement
• Chronic inflammatory conditions

CJC/Ipamorelin Candidates

• Men/women 40+ with low-normal IGF-1
• Poor recovery, body composition goals, disrupted sleep
• Patients who have completed foundational FM work and need the extra recovery boost

GHK-Cu Candidates

• Aging patients (naturally declining GHK-Cu levels)
• Collagen-related concerns, wound healing deficits
• TBI recovery, cognitive support in aging

GLP-1 Candidates

• Metabolic syndrome, obesity, insulin resistance, T2DM
• Beyond weight loss — metabolic inflammation is the FM angle
• Patients who have tried diet/lifestyle and need pharmacologic support

Contraindications / Cautions

• Active malignancy or cancer history (theoretical concern with GH secretagogues and angiogenesis-promoting peptides)
• Pregnancy (no safety data)
• Known peptide hypersensitivity
• Autoimmune flare states (case-by-case)

Monitoring Patient Response

Baseline Labs

Peptide Category	Key Baseline Labs
GH secretagogues (CJC/Ipamorelin)	IGF-1, comprehensive metabolic panel
Anti-inflammatory peptides (BPC, TB4, GHK-Cu)	hs-CRP, IL-6 if available
Metabolic peptides (GLP-1)	Fasting glucose, insulin, HbA1c, lipid panel
Gut peptides (BPC, KPV)	Zonulin, lactulose:mannitol, calprotectin if IBD suspected
All patients	CBC, CMP

Response Monitoring (4–8 Week Check-Ins)

• Symptom tracking (standardized questionnaire)
• Repeat relevant labs at 8 weeks (IGF-1 for CJC/Ipamorelin, hs-CRP for anti-inflammatory peptides)
• Patient-reported outcomes: sleep quality, energy, pain, GI symptoms
• Weight/body composition if applicable

Cycle Reassessment

• Most peptide protocols are 12–16 weeks
• Reassess at cycle end: continue, hold, or cycle off
• For patients on long-term protocols (e.g., aging patients on GHK-Cu), reassess every 6 months

The Legal and Regulatory Landscape

FDA Status Overview

• GLP-1 agonists: FDA-approved (Ozempic, Wegovy, Mounjaro) — different prescribing landscape
• All other peptides discussed: NOT FDA-approved for clinical use in humans

Compounding Pathway

• 503A pharmacies: Patient-specific compounding — highest standard, physician supervision required
• 503B pharmacies: Anticipatory compounding, larger batches — useful for established protocols

Recent FDA Actions

The FDA has attempted to restrict certain compounded peptides. BPC 157 was placed on the "difficult to compound" list in 2023 — significant regulatory development. As of early 2026, the status remains that 503A pharmacies cannot compound BPC 157 for office stock. Patient-specific compounds may still be available — consult your compounding pharmacy's regulatory counsel.

This landscape is evolving. Check FDA.gov and your compounding pharmacy's regulatory updates quarterly.

Informed Consent Requirements

• Document that patient understands off-label/research status
• Document compound source and batch number
• Document patient acknowledgment of risks and benefits
• Signed informed consent is standard of care

Billing Considerations

• Peptides are typically cash-pay
• Document as out-of-pocket services
• Some practitioners bundle into comprehensive FM protocol fees

Case Example

Patient: 48M, functional medicine patient with chronic tendinopathy (bilateral Achilles), leaky gut symptoms (bloating, loose stools, fatigue post-meals), and suboptimal recovery from CrossFit training. IGF-1 at 110 ng/mL (low-normal for age).

Protocol initiated:

• BPC 157 500 mcg/day SubQ × 12 weeks (Achilles + gut)
• CJC-1295/Ipamorelin 200 mcg each SubQ 5×/week pre-sleep

Monitoring:

• Baseline: hs-CRP 3.2 mg/L, IGF-1 110
• Week 8: hs-CRP 1.4 mg/L, IGF-1 178
• Patient reports: 60% improvement in Achilles pain, improved sleep quality, normalized bowel function

FAQ

Are peptides safe for long-term use? Most peptides have a favorable safety profile in animal studies and limited human data. Cycling (12–16 weeks on, break) is the clinical standard. Long-term safety data in humans is limited — practice accordingly.

Can I prescribe BPC 157 to my patients? BPC 157 is on the FDA's "difficult to compound" list. Patient-specific compounding may be available through some 503A pharmacies — verify with your compounding partner. If patients self-source, document that you are monitoring, not prescribing.

What's the difference between TB-500 and Thymosin Beta-4? TB-500 is a synthetic version of Thymosin Beta-4. TB-500 is the term typically used in research and compounding; TB4 is the naturally occurring form. They are used interchangeably in clinical practice.

How do I monitor for side effects?

• Injection site reactions (rotate sites, monitor for infection)
• GI symptoms with oral peptides
• Systemic symptoms (headache, fatigue — usually transient)
• For GH secretagogues: periodic IGF-1 monitoring, watch for fluid retention

Can peptides be combined with other FM protocols? Yes — peptides layer on top of foundational FM work (diet, gut healing, stress management). They complement rather than replace other interventions.

Peptide Therapy Toolkit — FM Overview

Peptide	Mechanism	Primary FM Indication	Route	Cycle
BPC 157	VEGF/angiogenesis, GH receptor sensitization, tight junction repair	Gut healing, tendinopathy, post-surgical	SubQ or oral	4–12 weeks
TB4 (TB-500)	Actin sequestration, NF-κB inhibition, M2 macrophage polarization	Systemic inflammation, neuroinflammation, post-COVID	SubQ	4–6 weeks loading
CJC-1295	GHRH analog, stimulates pituitary GH release	Body composition, recovery, anti-aging	SubQ	8–12 weeks
Ipamorelin	Ghrelin mimetic, selective GH release	Same as CJC-1295	SubQ	8–12 weeks
GHK-Cu	Gene regulation (>4,000 genes), anti-inflammatory	Aging, wound healing, cognitive support	SubQ, intranasal, topical	8–12 weeks
GLP-1	GLP-1 receptor agonism	Metabolic syndrome, weight, insulin sensitivity	SubQ (FDA-approved)	Per prescribing guidelines

---

This is the pillar article for the Peptide Therapy silo. For deeper dives, see: BPC 157 Healing Protocol, BPC 157 for Gut Healing, Peptides for Inflammation.

---

Ready to streamline complex protocol documentation? See how HANS handles peptide therapy notes — pre-built templates for each peptide, automated follow-up tracking, and lab result correlation built in.